Functional Dyspepsia in Helicobacter pylori Infection

This protocol covers the management of functional dyspepsia (FD) in patients with a confirmed Helicobacter pylori infection. The co-occurrence of H. pylori and FD requires a specific clinical approach that addresses both the infection and the underlying dyspeptic symptoms.

Patients presenting with functional dyspepsia in the setting of Helicobacter pylori infection. Eradication therapy is an efficacious treatment for H. pylori-positive patients with FD and is a recognised component of the structured management pathway for this population.

The protocol includes use of a tricyclic antidepressant acting as a gut-brain neuromodulator — an intervention class with a structured initiation and titration plan. The full sequence, eligibility criteria, and duration are detailed in the complete protocol.

Specific agent selection, dosing schedule, and monitoring guidance are available in the full structured protocol below.